
2023 Canadian Pharmaceutical Market Highlights



GENERICS SHARE = 76.6% OF THE MARKET, UP 2.3%



BRAND SHARE = 23.4% OF THE MARKET, DOWN 2.3%

Source: IQVIA. Canadian CompuScript. MAT December 2023

TOP 10 MOLECULES by Total Ethical Prescriptions, 2023

| RANK | PRODUCT | % CHANGE OVER 2022 |
|------|---------------------|-----------------------|
| 1 | ROSUVASTATIN | +7.5 |
| 2 | PANTOPRAZOLE | +4.9 |
| 3 | LEVOTHYROXINE | +1.0 |
| 4 | AMLODIPINE | +4.9 |
| 5 | ATORVASTATIN | +1.7 |
| 6 | CHOLECALCIFEROL | +1.8 |
| 7 | METFORMIN | +3.8 |
| 8 | METHADONE | -13.1 |
| 9 | ACETYLSALICYLIC ACI | D -1.4 |
| 10 | QUETIAPINE | +3.4 |

Source: IQVIA. Canadian CompuScript. MAT December 2023

2023 Canadian Pharmaceutical Market Highlights



BRAND GROWTH (+9.2%) GENERICS GROWTH (+9.6%)

Source: IQVIA. Canadian Drugstore and Hospital Audit. MAT December 2023

COMBINED RETAIL AND

HOSPITAL PURCHASES

Leading Therapeutic Classes in Retail and Hospital Purchases, 2023

| RANK | THERAPEUTIC CLASS | TOTAL PURCHASES (\$ MILLIONS) | % CHANGE OVER 2022 |
|------|---------------------------|-------------------------------------|-----------------------|
| 1 | ONCOLOGY | \$6,691 | +18.9 % |
| 2 | DIABETES THERAPY | \$4,183 | +20.8 % |
| 3 | ANTIARTHRITICS | \$3,586 | +2.3 % |
| 4 | IMMUNOLOGIC AGENT | S \$3,327 | +14.7 % |
| 5 | PSYCHOTHERAPEUTICS | \$3,132 | +9.8 % |
| 6 | RESPIRATORY THERAPY | \$1,996 | +6.6% |
| 7 | CARDIOVASCULARS | \$1,676 | +8.2 % |
| 8 | OPHTHALMICS | \$1,670 | +9.2 % |
| 9 | NEUROLOGICAL DISORDERS | \$1,645 | +12.6 % |
| 10 | ANTI-VIRALS | \$1,561 | +5.2% |

Source: IQVIA. Canadian Drugstore and Hospital Audit. MAT Dec 2023 DM

Retail Pharmacy Channels

Chains & Banners:

7,848

\$43.04 BILLION

UP 9.3%

Food/Mass merchandisers:

1,660

Independents:



Source: IQVIA Territorial Sales Analysis outlet count MAT Dec 2023 DM